--- title: "Evogene (EVGN) news: reverse split" url: "https://aibio.space/companies/evogene/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "EVGN reverse split news: Evogene gets extra 180 days from Nasdaq to fix bid price, to March 29, 2027. Evogene Ltd. (NASDAQ: EVGN), Israel." --- EVGN Evogene Ltd. NASDAQ · Israel # Evogene (EVGN) news EVGN reverse split news Listings · 2026-09-30 ## [Evogene gets extra 180 days from Nasdaq to fix bid price, to March 29, 2027](https://aibio.space/news/evogene-gets-extra-180-days-nasdaq-fix-bid-price-march-29-2027/) Nasdaq has given Evogene until March 29, 2027 to lift its ordinary shares back above $1.00. The company says it may consider a reverse split. In 2025 it used $13.5 million in operations, and year-end cash was $13.0 million. ## Latest Evogene news 1. 2026-07-31 Listings [Evogene calls September 4 meeting on director slates, share capital and reverse split](https://aibio.space/news/evogene-calls-september-4-meeting-director-slates-share-capital/) Evogene's board backs its own seven-person slate over a rival four-person slate at a September 4 meeting, and asks for 120,000,000 more authorized shares and a reverse split of 1-for-2 to 1-for-15. Year-end cash fell to $13.0 million in 2025. 2. 2025-08-19 Distress [Evogene cuts 30% of workforce, reports $11.7 million cash and $18.71 million ICL sale](https://aibio.space/news/evogene-cuts-30-percent-workforce-reports-11-7-million-cash-18-71/) Evogene is cutting 30% of its workforce and says an $18.71 million asset sale and a $4.4 million share program give it an 18-month runway. The $11.7 million cash figure leaves out the sale proceeds, and the company's equity attributable to shareholders is negative. ## Evogene at a glance - **Ticker**: EVGN - **Listing**: NASDAQ - **Country**: Israel - **Cash, Dec 31, 2025**: $13.0 million ### Related companies - [NRGENE TECHNOLOGIES LTD](https://aibio.space/companies/nrgene-technologies/) TASE: NRGN - [Compugen](https://aibio.space/companies/compugen/) NASDAQ: CGEN - [Pluri](https://aibio.space/companies/pluri/) NASDAQ: PLUR - [Chemomab Therapeutics](https://aibio.space/companies/chemomab-therapeutics/) NASDAQ: CMMB - [Regentis Biomaterials](https://aibio.space/companies/regentis-biomaterials/) AMEX: RGNT - [Kamada](https://aibio.space/companies/kamada/) NASDAQ: KMDA - [Polyrizon](https://aibio.space/companies/polyrizon/) NASDAQ: PLRZ - [Matricelf](https://aibio.space/companies/matricelf/) TASE: MTLF ### Also on NASDAQ - [Rallybio](https://aibio.space/companies/rallybio/) RLYB - [Black Diamond Therapeutics](https://aibio.space/companies/black-diamond-therapeutics/) BDTX - [Tvardi Therapeutics](https://aibio.space/companies/tvardi-therapeutics/) TVRD - [Disc Medicine](https://aibio.space/companies/disc-medicine/) IRON - [Spyre Therapeutics](https://aibio.space/companies/spyre-therapeutics/) SYRE - [Cadrenal Therapeutics](https://aibio.space/companies/cadrenal-therapeutics/) CVKD ## Evogene annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$3.9 million](https://www.sec.gov/Archives/edgar/data/1574565/000117891326001767/) | [$5.6 million](https://www.sec.gov/Archives/edgar/data/1574565/000117891326001767/) | | Research and development | [$8.0 million](https://www.sec.gov/Archives/edgar/data/1574565/000117891326001767/) | [$12.5 million](https://www.sec.gov/Archives/edgar/data/1574565/000117891326001767/) | | Net income (loss) | [-$7.8 million](https://www.sec.gov/Archives/edgar/data/1574565/000117891326001767/) | [-$18.1 million](https://www.sec.gov/Archives/edgar/data/1574565/000117891326001767/) | | Cash from operations | [-$13.5 million](https://www.sec.gov/Archives/edgar/data/1574565/000117891326001767/) | [-$19.7 million](https://www.sec.gov/Archives/edgar/data/1574565/000117891326001767/) | | Cash and equivalents | [$13.0 million](https://www.sec.gov/Archives/edgar/data/1574565/000117891326001767/) | [$15.3 million](https://www.sec.gov/Archives/edgar/data/1574565/000117891326001767/) | Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $13.0 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Evogene Did Evogene do a reverse stock split? Our latest story on this, dated Sep 30, 2026: "Evogene gets extra 180 days from Nasdaq to fix bid price, to March 29, 2027". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/evogene-gets-extra-180-days-nasdaq-fix-bid-price-march-29-2027/). What is the ticker symbol of Evogene? Evogene Ltd. trades under the ticker EVGN on NASDAQ. Where is Evogene listed? Evogene Ltd. is listed on NASDAQ. Our directory also records these other listings: TASE:EVGN. What is the SEC CIK of Evogene? The SEC Central Index Key (CIK) for Evogene Ltd. is 1574565. Its filings are on SEC EDGAR. How many shares does Evogene have outstanding? 8,718,193 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-26. Which country or territory is Evogene listed under? Our directory records Evogene Ltd. under Israel. What does Evogene do? Our directory classifies Evogene Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Evogene? The ISIN recorded for Evogene Ltd. is IL0011050551. Does aibio.space cover Evogene? aibio.space lists Evogene Ltd. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Evogene incorporated? SEC records list its state or country of incorporation as L3. What was Evogene's revenue last year? $3.9 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Evogene profitable? Evogene Ltd. reported a net loss of $7.8 million for the fiscal year ended Dec 31, 2025, and used $13.5 million of cash in operations, per its annual report to the SEC. How much does Evogene spend on research and development? $8.0 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Evogene have? $13.0 million in cash at Dec 31, 2025, per its 20-F. What is the latest Evogene (EVGN) stock news? Our latest story on Evogene, dated Sep 30, 2026: "Evogene gets extra 180 days from Nasdaq to fix bid price, to March 29, 2027". Nasdaq has given Evogene until March 29, 2027 to lift its ordinary shares back above $1.00. The company says it may consider a reverse split. In 2025 it used $13.5 million in operations, and year-end cash was $13.0 million. [Source](https://aibio.space/news/evogene-gets-extra-180-days-nasdaq-fix-bid-price-march-29-2027/). ## Investor discussion: Evogene Members talk about Evogene (EVGN). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Evogene, newest first. Each line links the filing it comes from. 1. 2026-10-06 Mergers Reported a merger or acquisition agreement. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1574565/000117891326004722/exhibit_99-1.htm) 2. 2026-09-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1574565/000117891326004654/exhibit_99-1.htm) 3. 2026-09-15 Mergers Reported a merger or acquisition agreement. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1574565/000117891326004516/zk2636119.htm) 4. 2026-07-31 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1574565/000117891326003741/exhibit_99-1.htm) 5. 2026-07-17 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1574565/000117891326003516/zk2635697.htm) 6. 2026-04-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1574565/000117891326001981/exhibit_99-1.htm) 7. 2025-08-19 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1574565/000117891325002976/exhibit_99-1.htm) 8. 2025-06-05 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1574565/000117891325002109/zk2533327.htm) 9. 2025-04-21 Mergers Reported a merger or acquisition agreement. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1574565/000117891325001340/exhibit_99-1.htm) 10. 2025-03-27 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. [Source](https://www.sec.gov/Archives/edgar/data/1574565/000117891325001092/zk2532892.htm) 11. 2024-11-21 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1574565/000117891324003796/exhibit_99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:EVGN on TradingView](https://www.tradingview.com/symbols/NASDAQ-EVGN/). ## SEC filings and registration - **SEC name**: Evogene Ltd. - **CIK**: 1574565 - **Industry (SIC)**: Agricultural Chemicals (2870) - **US tickers**: EVGN (Nasdaq) - **State or country of incorporation**: L3 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer - **Business address**: 13 GAD FEINSTEIN STREET, REHOVOT, Israel, 7638517 - **Phone**: 97289311900 - **Shares outstanding**: 8,718,193 as of 2025-12-31 (20-F filed 2026-03-26) ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1574565/000117891326004722/zk2636203.htm) filed 2026-10-06 - [6-K](https://www.sec.gov/Archives/edgar/data/1574565/000117891326004654/zk2636176.htm) filed 2026-09-30 - [6-K](https://www.sec.gov/Archives/edgar/data/1574565/000117891326004636/zk2636149.htm) filed 2026-09-28 - [6-K](https://www.sec.gov/Archives/edgar/data/1574565/000117891326004516/zk2636119.htm) filed 2026-09-15 - [6-K](https://www.sec.gov/Archives/edgar/data/1574565/000117891326004425/zk2636082.htm) filed 2026-09-04 - [6-K](https://www.sec.gov/Archives/edgar/data/1574565/000117891326004270/zk2636020.htm) filed 2026-08-27 - [6-K](https://www.sec.gov/Archives/edgar/data/1574565/000117891326004174/zk2635981.htm) filed 2026-08-18 - [6-K](https://www.sec.gov/Archives/edgar/data/1574565/000117891326003741/zk2635808.htm) filed 2026-07-31 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001574565), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Evogene Ltd. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker EVGN, recorded under Israel. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Evogene Ltd. - **Ticker**: EVGN - **Listing**: NASDAQ - **Country or territory**: Israel - **Business scope**: Biotechnology - **ISIN**: IL0011050551 - **Other listed symbols**: TASE:EVGN - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-EVGN/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/evogene/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Evogene (EVGN) news: reverse split", 2026-10-31, https://aibio.space/companies/evogene/